Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/62806
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill |
Author: | Deane, A. Chapman, M. Horowitz, M. |
Citation: | Critical Care (UK), 2010; 14(5):1-3 |
Publisher: | Current Science Ltd |
Issue Date: | 2010 |
ISSN: | 1466-609X 1466-609X |
Statement of Responsibility: | Adam M Deane, Marianne J Chapman and Michael Horowitz |
Abstract: | Glucagon-like peptide-1 (GLP-1), a principal mediator of the postprandial insulinotropic response in health, has a half-life of minutes. The saliva of the Gila monster contains exendin-4, a structural analogue of human GLP-1, but with a much longer half-life. A synthetic preparation of exendin-4, exenatide, is suitable for human use and effectively lowers glucose in ambulant type 2 diabetic patients. When compared with insulin, exenatide therapy is associated with a reduction in hypoglycaemic episodes and postprandial glycaemic excursions in this group. Accordingly, GLP-1 analogues are appealing therapies for hyperglycaemia in the critically ill patient and warrant further study. |
Keywords: | Venoms Animals Humans Lizards Reptilian Proteins Glucagon-Like Peptide 1 |
Description: | Commentary |
Rights: | © 2010 BioMed Central Ltd |
DOI: | 10.1186/cc9281 |
Published version: | http://dx.doi.org/10.1186/cc9281 |
Appears in Collections: | Anaesthesia and Intensive Care publications Aurora harvest |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_62806.pdf | Published version | 128.51 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.